SFDA Spells Out Tasks For 2009
This article was originally published in PharmAsia News
China's State FDA will concentrate on improving the regulation of standards and supervision of food and drugs in 2009, with the aim of raising standards for all drugs marketed within five years. The agency will speed up its action plan by strengthening international cooperation on formulating standards; revising or raising the quality level of 2,000 drugs; and revising the 2010 Chinese Pharmacopoeia edition. In addition, SFDA will finish the revision of Regulations for the Supervision and Administration of Medical Devices; conduct research on revising the Drug Administration Law and Regulations for the Hygiene Supervision on Cosmetics; implement Provisions for Drug Registration and its complementary documents; as well as continuously formulate and standardize technical appraisal guidelines for drugs and medical devices. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.